Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
McKinsey
AstraZeneca
Harvard Business School

Last Updated: September 25, 2022

LASTACAFT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Lastacaft, and when can generic versions of Lastacaft launch?

Lastacaft is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcaftadine profile page.

DrugPatentWatch® Generic Entry Outlook for Lastacaft

Lastacaft was eligible for patent challenges on July 28, 2014.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2027. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for LASTACAFT
Drug Prices for LASTACAFT

See drug prices for LASTACAFT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LASTACAFT
Generic Entry Date for LASTACAFT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LASTACAFT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Allergan
ORA, Inc.Phase 4
Starx Research Center, LLCPhase 4

See all LASTACAFT clinical trials

Pharmacology for LASTACAFT
Anatomical Therapeutic Chemical (ATC) Classes for LASTACAFT
Paragraph IV (Patent) Challenges for LASTACAFT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LASTACAFT Ophthalmic Solution alcaftadine 0.25% 022134 1 2014-07-30

US Patents and Regulatory Information for LASTACAFT

LASTACAFT is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of LASTACAFT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting LASTACAFT

Ophthalmic compositions containing alcaftadine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER

Ocular allergy treatments with alcaftadine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LASTACAFT

When does loss-of-exclusivity occur for LASTACAFT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 0278
Estimated Expiration: See Plans and Pricing

Patent: 1697
Estimated Expiration: See Plans and Pricing

Australia

Patent: 07234957
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0710085
Estimated Expiration: See Plans and Pricing

Canada

Patent: 48115
Estimated Expiration: See Plans and Pricing

Chile

Patent: 07000916
Estimated Expiration: See Plans and Pricing

China

Patent: 1460176
Estimated Expiration: See Plans and Pricing

Patent: 2895234
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 414
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 04196
Estimated Expiration: See Plans and Pricing

Patent: 50209
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 088786
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 6221
Estimated Expiration: See Plans and Pricing

Patent: 0870396
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 04196
Estimated Expiration: See Plans and Pricing

Patent: 50209
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 31331
Estimated Expiration: See Plans and Pricing

Israel

Patent: 4473
Estimated Expiration: See Plans and Pricing

Japan

Patent: 92277
Estimated Expiration: See Plans and Pricing

Patent: 39716
Estimated Expiration: See Plans and Pricing

Patent: 09533333
Estimated Expiration: See Plans and Pricing

Patent: 13144703
Estimated Expiration: See Plans and Pricing

Patent: 15131820
Estimated Expiration: See Plans and Pricing

Jordan

Patent: 58
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 3669
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 08012657
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 1690
Estimated Expiration: See Plans and Pricing

Nicaragua

Patent: 0800261
Estimated Expiration: See Plans and Pricing

Norway

Patent: 1147
Estimated Expiration: See Plans and Pricing

Patent: 084593
Estimated Expiration: See Plans and Pricing

Peru

Patent: 080053
Estimated Expiration: See Plans and Pricing

Poland

Patent: 04196
Estimated Expiration: See Plans and Pricing

Patent: 50209
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 0044
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0809327
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1321731
Estimated Expiration: See Plans and Pricing

Patent: 080110881
Estimated Expiration: See Plans and Pricing

Spain

Patent: 94655
Estimated Expiration: See Plans and Pricing

Patent: 52823
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 50721
Estimated Expiration: See Plans and Pricing

Patent: 78990
Estimated Expiration: See Plans and Pricing

Patent: 0815016
Estimated Expiration: See Plans and Pricing

Patent: 1446249
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 938
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 254
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LASTACAFT around the world.

Country Patent Number Title Estimated Expiration
China 1068118 See Plans and Pricing
Hungary 221016 Imidazo[2,1-b][3]benzazepin-származékok, ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierek (IMIDAZO[2,1-B][3]BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING, AND PROCESS FOR PREPARING THEM AND INTERMEDIATES) See Plans and Pricing
Yugoslavia 61192 See Plans and Pricing
Spain 2207632 See Plans and Pricing
Spain 2594655 See Plans and Pricing
Spain 2752823 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.